Skip to main content
Premium Trial:

Request an Annual Quote

Waters Signs Mass Spec, Software, LC Purchase Deal with Indian CRO

NEW YORK (GenomeWeb News) — Waters will provide mass spectrometry equipment and training to the clinical research services company Lambda Therapeutics Research when Lambda lands service contracts, a Waters spokesman told GenomeWeb Daily News today.
The agreement  “paves the way” for Ahmedabad, India-based Lambda to purchase Waters’ Quattro Premier XE tandem quadrupole mass spectrometer, Acquity UPLC system, and MassLynx software for use in analyzing complex biological samples, Waters spokesman Jeff Tarmy said.
“The agreement enables Lambda to meet its international business goals by fulfilling its needs for innovative laboratory equipment, including mass spectrometry, liquid chromatography, and laboratory software solutions,” the company said in a statement yesterday.
Tarmy said the plan means that “the agreements are in place” for Lambda to buy the tools, training, and knowledge, and that a pathway has been set for Lambda to handle orders as they come in.
Lambda works as a clinical research services partner with pharmaceutical companies, and has facilities in Mumbai, Chennai, and in Warsaw, Poland.
Financial terms of the agreement were not released.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.